Evaluation of the pharmacokinetic and pharmacodynamic interactions of commonly co-administered drugs in polypharmacy among elderly patients: a prospective clinical study

Project Abstract

This prospective clinical study investigates the pharmacokinetic (PK) and pharmacodynamic (PD) interactions arising from polypharmacy among elderly patients, aiming to delineate how co-administered drugs alter exposure, efficacy, and safety profiles in real-world settings. A cohort of individuals aged 65 and older receiving multiple concomitant medications was enrolled from outpatient clinics and long-term care facilities, with careful stratification by comorbidity burden, number of daily medications, and renal/hepatic function. PK analyses concentrated on commonly prescribed drug classes in geriatrics, including anticoagulants, antidiabetics, antihypertensives, statins, antidepressants, and antiplatelet agents. Serial blood sampling and sparsely sampled pharmacokinetic modeling were employed to quantify absorption, distribution, metabolism, and elimination parameters, with a focus on cytochrome P450-mediated interactions and transporter effects in the gut and liver. PD endpoints encompassed therapeutic outcomes and adverse event profiles, such as bleeding risk, hypoglycemia, hypotension, QT interval prolongation, and cognitive or delirium-related events, integrated with pharmacometric modeling to correlate PK variability with clinical effects. Comprehensive data collection included concomitant non-prescription substances, renal function markers, body mass index, nutritional status, and adherence patterns, enabling construction of exposure–response and dose–response relationships under polypharmacy conditions. Advanced statistical methods, including nonlinear mixed-effects modeling and machine learning algorithms, were applied to identify significant interaction signals, quantify interaction magnitude, and classify drug pairs with clinically meaningful impact. The study further investigates genetic polymorphisms in drug-metabolizing enzymes (e.g., CYP2C9, CYP2D6) and transporters (e.g., P-glycoprotein) to explain interindividual variability in PK/PD responses. Sensitivity analyses addressed confounding factors such as age-related physiological changes, polypharmacy duration, and comorbidity therapies. Findings are expected to reveal specific drug–drug interaction patterns that modify bioavailability, clearance, or receptor sensitivity, thereby altering therapeutic windows and adverse event probabilities in the elderly. The study will propose evidence-based strategies for risk stratification, individualized dosing adjustments, and monitoring protocols (e.g., timing of dosing, therapeutic drug monitoring, and phenotyping for high-risk metabolic pathways) to optimize safety and efficacy in polypharmacy. Ethical considerations include informed consent, minimization of blood draw burden through optimized sampling schedules, and data privacy safeguards. Potential limitations involve observational design constraints, residual confounding, and heterogeneity in clinical practice across sites. Ultimately, the research aims to generate actionable insights for clinicians to predict PK/PD alterations due to co-medications, reduce adverse drug events, and improve therapeutic outcomes for elderly patients navigating complex pharmacotherapy regimens.

Project Overview

What This Project Is About

---

Investigates how older adults who take many medicines at once may experience interactions between drugs. It looks at how these interactions change how drugs behave in the body and how they affect effects and safety.

---

---

The Problem It Addresses

---

Many elderly people take multiple drugs daily, which can lead to interactions that alter drug levels or effects. These interactions can increase side effects or reduce effectiveness, posing risks to health and quality of life.

---

---

Objectives of the Project

---

1. Identify common drugs used together by older adults in real clinical practice.
2. Describe how these drug combinations may interact pharmacokinetically (how the body handles drugs) and pharmacodynamically (how drugs affect the body).
3. Assess potential safety concerns such as increased side effects or reduced therapeutic benefit.

---

---

What You Will Do Step by Step

---

1) Review existing literature to list typical drug pairs used by elderly patients. 2) Collect anonymized patient data on prescriptions and outcomes. 3) Map possible interactions based on known drug properties. 4) Analyze data for patterns linking polypharmacy to adverse effects or poor control of conditions. 5) Summarize findings and discuss practical implications for safer prescribing.

---

---

Expected Outcome

Clear identification of high-risk drug combinations in elderly patients, practical guidelines to reduce harmful interactions, and recommendations for clinicians to improve medication safety and effectiveness.